Chemogenomics - Pharmacology with genomics tools

Drug Discovery Today: TARGETS

Volumn 1, Issue 2, 2002, Pages 59-65

  Browne, Leslie J ^a   Furness, L Michael ^a   Natsoulis, George ^a   Pearson, Cecelia ^a   Jarnagin, Kurt ^a  

^a Entelos Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER;

DATA BASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUSTRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENOMICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL LITERATURE; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PROTEOMICS; REVIEW; SIDE EFFECT; TOXICOLOGY;

EID: 0038273551     PISSN: 17418372     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1477-3627(02)02245-6     Document Type: Review

References (32)

1. Schreiber, S.L. (1998) Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg. Med. Chem. 6, 1127-1152
2. Alaimo, P.J. et al. (2001) Chemical genetic approaches for the elucidation of signaling pathways. Curr. Opin. Chem. Biol. 5, 360-367
3. Caron, P.R. et al. (2001) Chemogenomic approaches to drug discovery. Curr. Opin. Chem. Biol. 5, 464-470
4. Alaoui-Ismaili, M.H. et al. (2002) Chemical genomics: discovery of disease genes and drugs. Drug Discov. Today 7, 292-294
5. Murcko, M. and Caron, P. (2002) Transforming the genome to drug discovery. Drug Discov. Today 7, 583-584
6. Zanders, E.D. et al. (2002) Probes for chemical genomics by design. Drug Discov. Today 7, 711-718
7. Drews, J. (2000) Drug discovery: a historical perspective. Science 287, 1960-1964
8. Cohen, S.N. et al. (1973) Construction of biologically functional bacterial plasmids in vitro. Proc. Natl. Acad. Sci. U. S. A. 70, 3240-3244
9. Fitzgerald, J.D. (1976) Beta-blockade and mechanisms of disease. Postgrad. Med. J. 52 (Suppl. 4), 184-190
10. Cushman, D.W. and Ondetti, M.A. (1999) Design of angiotensin converting enzyme inhibitors. Nat. Med. 5, 1110-1113
11. Black, J.W. et al. (1972) Definition and antagonism of histamine H2-receptors. Nature 236, 385-390
12. Bartosiewicz, M.J. et al. (2001) Unique gene expression patterns in liver and kidney associated with exposure to chemical toxicants. J. Pharmacol. Exp. Ther. 297, 895-905
13. Waring, J.F. et al. (2001) Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol. Appl. Pharmacol. 175, 28-42
14. Waring, J.F. et al. (2001) Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 120, 359-368
15. Furness, L.M. (2002) Genomics applications that facilitate the understanding of drug action and toxicity. In Pharmacogenomics: the Search for Individualized Therapy (Licinio, J. and. Wong, M.-L. eds) Wiley-VCH Press.
16. Furness, L.M. (2002) Analysis of gene and protein expression for drug mode of toxicity. Curr. Opin. Drug Discov. Devel. 5, 98-103
17. Farr, S. et al. (1999) Concise review: gene expression applied to toxicology. Toxicol. Sci. 50, 1-9
18. Gould Rothberg, B.E. (2001) The use of animal models in expression pharmacogenomics analyses. Pharmacogenomics J. 1, 48-58
19. Castle, A.L. et al. (2002) Toxicogenomics: a new revolution in drug safety. Drug Discov. Today 7, 728-736
20. Bristol, D.W. et al. (1996) The NIEHS predictive-toxicology evaluation project. Environ. Health Perspect. 104 (Suppl. 5), 1001
21. Tennant, R. (2002) The National Center for Toxicogenomics: Using new technologies to inform mechanistic toxicology. Environ. Health Perspect. 110, A8-A10
22. Scherf, U. et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24, 236-244
23. Weinstein, J.N. et al. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343-349
24. Fielden, M.R. et al. (2001) Challenges and limitations of gene expression profiling in mechanistic and predicitive toxicology. Toxicol. Sci. 60, 6-10
25. Gerhold, D. et al. (2001) Monitoring expression of genes involved in drug metabolism and toxicology using DNA micorarrays. Physiol. Genomics 5, 161-170
26. Lovett, R.A. (2000) Toxicologists brace for genomics revolution. Science 289, 536
27. MacGregor, J.T. et al. (2001) In vitro tissue models in risk assessment: report of a consensus-building workshop. Toxicol. Sci. 59, 17-36
28. Huang, Q. et al. (2001) Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci. 63, 196-207
29. Reilly, T.P. et al. (2001) Expression profiling of acetaminophen liver toxicity in mice using microarray technology. Biochem. Biophys. Res. Commun. 282, 321-328
30. Bulera, S.J. et al. (2001) RNA expression in the early characterization of hepatotoxicants in Wistar rats by high-density DNA microarrays. Hepatology 33, 1239-1258
31. Furness, L.M. et al. Chemogenomics for Predictive Drug Assessment. (in press)
32. Mahley, R.W. and Bersot, T.P. (2001) Drug therapy for hypercholesterolemia and dyslipdeamia. In Goodman & Gilman: The Pharmacological Basis of Therapeutics, Edition. 10 (Hardman, J.G. and Limbird, L.E., eds), pp 971-1002, McGraw Hill